Vicarious Surgical, Inc. · OTC:RBOT

Vicarious Surgical — Investor Presentation (February 2023)

26 slides from Vicarious Surgical's investor presentation, February 2023

  1. Slide 1: Vicarious Surgical Investor Presentation February 2023

    VICARIOUS SURGICAL INVESTOR PRESENTATION FEBRUARY 2023

  2. Slide 2: Disclaimer

    Vv DISCLAIMER This presentation includes “forward-looking statements" within the meaning of the ‘safe harbar” provisions of the United States Private Securities Litigation Reform Act of 1995. The company’s ‘actual results may differ from its expectations, estimates, and projections and, consequently

  3. Slide 3: Key Investment Summary

    Vv KEY INVESTMENT ( )) NEXT GENERATION ROBOTICS TECHNOLOGY 4 DESIGNED TO SOLVE MANUAL AND ROBOT-ASSISTED +5 =-- SURGERY SHORTCOMINGS DA TAPPING INTO A (M $136B MARKET; 96.8% “@- UNADDRESSED BY ROBOTICS! - ey [1] VICARIOUS ESTIMATES FROM DATA SOURCED FROM LSI MARKET SIZE ANALYSIS AND PUBLIC FILINGS,

  4. Slide 4: Our Team and Investors

    _, OUR TEAM AND VICARIOUS SURGICAL INVESTOR PRESENTATION FEBRUARY 2023,

  5. Slide 5: Visionary Management Team

    Vv VISIONARY MANAGEMENT TEAM e re] » \ CHIEF FINANCIAL OFFICER GENERAL COUNSEL AND VP OF PRODUCT DESIGN AND. BILL KELLY CHIEF LEGAL OFFICER COMMERCIALIZATION JUNE MORRIS MICHAEL PRATT BREPLIGEN Qeoemes, BY A =e@PICIs AM PEGA @ INTUITIVE @2_wer Pome HAEMONETICS’ Deloitte. CO-FOUNDER, CHIEF VP OF OPER

  6. Slide 6: Experienced Board and Advisors; Seasoned Investors

    Vv EXPERIENCED BOARD AND ADVISORS B £ |S EXECUTIVE CHAIRMAN De BOARD DIRECTOR BOARD DIRECTOR ‘BOARD DIRECTOR BOARD DIRECTOR DAVID STYKA DAVID HO SAMMY KHALIFA ADAM SACHS RIC FULOP AURIS ews Caltech MIT liz Noted HIV/AIDS: Researcher; Time “Man of the Year” 1996 &eRAR @ Nir BBR, Desktop Metal Former

  7. Slide 7: The Problem

  8. Slide 8: The State of Surgery Today

    Vv THE STATE OF SURGERY TODAY .... THE BEGINNING OPEN SURGERY Weeks Large incision at home and months of pain Injuries High Pain cost of care Complications COMPLICATION RATES > 1 FROM INCISION 15-20% MINIMALLY- INVASIVE SURGERY Monual and Robotic % Smallincision Multiple incisions VY Less injuries L

  9. Slide 9: Limitations of Robotic Surgery Today

    V LIMITATIONS OF ROBOTIC SURGERY TODAY : HIGH COST DIFFICULT TO USE Capital and service costs Steep learning curves and >$2M investment device-specific training requirements High upfront cost and burdensome service Surgeon is required to “design contracts are often robot motion” for each prohibitive

  10. Slide 10: Our Solution

    3 OUR SOLUTION VICARIOUS SURGICAL INVESTOR PRESENTATION FEBRUARY 2023,

  11. Slide 11: Slide 11

  12. Slide 12: The System

    Vv THE SYSTEM 9 1.5cm 3560 DEGREES OF SINGLE DEGREES FREEDOM PER ARM INCISION VIEW LOWER YEARS CAPITAL COST? OF R&D 50+ 34’wide 28 PATENTS ISSUED FITS THROUGH ANY SENSORS PER ARM AND PENDINGS STANDARD DOOR INSIDE PATIENT [1] VICARIOUS SYSTEM IS CAPABLE OF INCISION SIZES AS LOW AS 1.2CH. CURRENT DISP

  13. Slide 13: Video Link

    VIDEO LINK VIDEO LINK VIDEO LINK

  14. Slide 14: Size

    Vv SIZE Simple, portable, and capable—the Vicarious Surgical robot fits through a standard door and can fit into surgical facilities without construction buildout LEGACY SURGICAL ROBOTS VICARIOUS SURGICAL ROBOTS VICARIQUS SURGICAL INVESTOR PRESENTATION FEBRUARY 2023 03 | OUR SOLUTION

  15. Slide 15: 360° Reach and View

    Vv 360° REACH AND VIEW The Vicarious Surgical robot can work anywhere in the abdomen through a 1.5cm! incision The 9 decoupled actuators in each arm provide unprecedented dexterity inside of an ultra thin support tube unre LaRce workins working AREA AREA LEGACY SINGLE VICARIOUS PORT ROBOTS SURGICAL

  16. Slide 16: Sensing and Visualization

    SENSING AND VISUALIZATION 3D DEPTH MAPPING FULL MOTION FORCE SENSING TRACKING + FEEDBACK AT EVERY JOINT © © 4K HIGH FRAME WIDE FOV AUTOFOCUS RATE © MULTISPECTRAL TONE ADJUSTING HEAD MOUNTED IMAGING LIGHTING DISPLAY! & DISPLAY (IIWHILE CAPABLE OF HEAD HOUNTED DISPLAY CURRENTLY, HEAD MOUNTED DISPLAY W

  17. Slide 17: Economics

    ECONOMICS Advanced engineering enables sterile portion to be disposable or reposable with competitive cost structure + 3D printed and injection molded parts with polymer fiber cables + Decoupled actuators enable polymer cables and parts, lowering part costs vs traditional manufacturing over 5-10x' -

  18. Slide 18: Market Research: Features

    Vv MARKET RESEARCH FEATURES Surgeons and administrators reacted positively to the features that our surgical robot provides. Their favorite features are unique to our technology llike it because it can articulate in 360° and provides a camera that allows for instruments to always be in view = GENERA

  19. Slide 19: Market Research: Competitor Comparison

    Vv MARKET RESEARCH COMPETITOR COMPARISON ~~ —) Independent blinded study with surgeons and hospitals shows over 4 out of 5 score (very easy sell), well above competing solutions SOURCE: BLINDED STUDY PERFORMED BY THIRD PARTY RESEARCH FIRM VICARIOUS SURGICAL INVESTOR PRESENTATION FEBRUARY 2023, VERY

  20. Slide 20: Our Pathway to Commercialization

    og OUR PATHWAY 10 COMMERCIALIZATION VICARIOUS SURGICAL INVESTOR PRESENTATION FEBRUARY 2023,

  21. Slide 21: Expected Roadmap

    Vv EXPECTED ROADMAP nitial Manufacturing DEVELOPMENT AND REGULATORY Filing FDA submis Producti (ie on Build Launch of Early ‘Adopter Program hKOL Y Surgeons Simulator Launch Executed COMMERCIAL, GROWTH AND CLINICAL, Manufacturin — — — Cleanroom Setup: d Cleanroom Validated v NOTE: ACTUAL MILESTONES

  22. Slide 22: Center of Excellence Agreements

    Vv CENTER OF EXCELLENCE AGREEMENTS WORKING TOGETHER TO REFINE THE PATIENT, SURGEON AND HOSPITAL VALUE OF THE VICARIOUS SURGICAL ECOSYSTEM FOR FUTURE STREAMLINED ADOPTION @ 5 PRODUCT DEVELOPMENT: LEVERAGE ADMINISTRATIVE, OPERATIONAL, AND CLINICAL FEEDBACK FOR REFINEMENT VERIFICATION & VALIDATION: OPE

  23. Slide 23: Our Market, Our Potential

    OUR MARKET, OUR POTENTIAL 05 VICARIOUS SURGICAL INVESTOR PRESENTATION FEBRUARY 2023,

  24. Slide 24: First Indication: Ventral Hernia

    Vv FIRST INDICATION: VENTRAL HERNIA MARKET SIZE! 0.9M US VENTRAL HERNIA CASES 5.5M OUTSIDE US VENTRAL HERNIA CASES [1] VICARIOUS ESTIMATES FROM LSI MARKET DATA, INCLUDES INCISIONAL ANO UMBILICAL. HERNIA CASES, 2020 DATA [2] MEDICARE.GOV CODES 49652, 49654, 49654+BILATERAL 18734 [3] LAVANCHY £7 AL: L

  25. Slide 25: Initial Addressable Market

    Vv INITIAL ADDRESSABLE MARKET TOTAL INITIAL ADDRESSABLE MARKET S136B’ ADDRESSABLE PROCEDURES TARGET ~11.5M GALLBLADDER PROCEDURES* (~2.3M US) ~7.0M ALL OTHER HERNIA® (-1.5M US} ~4.1M 2.7 VENTR: HYSTERECTOMY: HERNIA’ (-0.6M US) (-0.9m us) 59M ABDOMINAL PROCEDURES ADDRESSABLE BY VICARIOUS” ~13.4M GI P

  26. Slide 26: Thank You

    THANK YOU VICARIOUS SURGICAL 78 Fourth Avenue vicarioussurgical.com Waltham, MA, 02451 +1.617.868.1700 VICARIOUS SURGICAL INVESTOR PRESENTATION FEBRUARY 2023,

Vicarious Surgical — Investor Presentation (February 2023) on 6ix